These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 9047384)
21. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375 [TBL] [Abstract][Full Text] [Related]
22. Role of Dok1 in cell signaling mediated by RET tyrosine kinase. Murakami H; Yamamura Y; Shimono Y; Kawai K; Kurokawa K; Takahashi M J Biol Chem; 2002 Sep; 277(36):32781-90. PubMed ID: 12087092 [TBL] [Abstract][Full Text] [Related]
23. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871 [TBL] [Abstract][Full Text] [Related]
24. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine. Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105 [TBL] [Abstract][Full Text] [Related]
25. The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. Melillo RM; Carlomagno F; De Vita G; Formisano P; Vecchio G; Fusco A; Billaud M; Santoro M Oncogene; 2001 Jan; 20(2):209-18. PubMed ID: 11313948 [TBL] [Abstract][Full Text] [Related]
27. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368 [TBL] [Abstract][Full Text] [Related]
28. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases. Kato M; Iwashita T; Takeda K; Akhand AA; Liu W; Yoshihara M; Asai N; Suzuki H; Takahashi M; Nakashima I Mol Biol Cell; 2000 Jan; 11(1):93-101. PubMed ID: 10637293 [TBL] [Abstract][Full Text] [Related]
29. Cell signalling and gene expression mediated by RET tyrosine kinase. Kurokawa K; Kawai K; Hashimoto M; Ito Y; Takahashi M J Intern Med; 2003 Jun; 253(6):627-33. PubMed ID: 12755958 [TBL] [Abstract][Full Text] [Related]
30. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703 [TBL] [Abstract][Full Text] [Related]
31. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555 [TBL] [Abstract][Full Text] [Related]
32. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641 [TBL] [Abstract][Full Text] [Related]
33. Tyrosines outside the kinase core and dimerization are required for the mitogenic activity of RET/ptc2. Durick K; Yao VJ; Borrello MG; Bongarzone I; Pierotti MA; Taylor SS J Biol Chem; 1995 Oct; 270(42):24642-5. PubMed ID: 7559572 [TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of RET activation in human cancer. Santoro M; Melillo RM; Carlomagno F; Fusco A; Vecchio G Ann N Y Acad Sci; 2002 Jun; 963():116-21. PubMed ID: 12095936 [TBL] [Abstract][Full Text] [Related]
35. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. Segouffin-Cariou C; Billaud M J Biol Chem; 2000 Feb; 275(5):3568-76. PubMed ID: 10652352 [TBL] [Abstract][Full Text] [Related]
36. Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. Pandey A; Liu X; Dixon JE; Di Fiore PP; Dixit VM J Biol Chem; 1996 May; 271(18):10607-10. PubMed ID: 8631863 [TBL] [Abstract][Full Text] [Related]
37. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Bongarzone I; Vigano E; Alberti L; Mondellini P; Uggeri M; Pasini B; Borrello MG; Pierotti MA Oncogene; 1999 Aug; 18(34):4833-8. PubMed ID: 10490816 [TBL] [Abstract][Full Text] [Related]